Lyell reports 94% ORR, 71% CR for IMPT-314 in Phase 1-2 large B-cell lymphoma trial

Lyell Immunopharma, Inc.

Objective response rate 94% (16/17) and complete response rate 71% (12/17) in CAR T-naive patients with ≥2 prior therapies.
No Grade 3+ cytokine release syndrome; Grade 3 ICANS in 13% (3/23) with median resolution time of 5 days.
Median follow-up 6.3 months; 71% of patients remained in response at last follow-up.
Plans to initiate a pivotal trial in 2025 for 3rd-line+ large B-cell lymphoma and continues 2nd-line evaluation.
Final product enriched for naïve/central memory T cells (median 91%), linked to improved overall survival in other studies.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.